Novanta Inc.
128.61+0.93 (+0.73%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · NOVT · USD
Key Stats
Market Cap
4.63BP/E (TTM)
76.10Basic EPS (TTM)
1.69Dividend Yield
0%Recent Filings
8-K
Board director resigns
Novanta Inc. announced Barbara Hulit's resignation from its Board of Directors, Audit Committee, and ESG Committee, effective November 1, 2025. The move stems from personal reasons, with no disagreements over operations, policies, or practices. Board refresh. This change maintains continuity amid the company's steady governance.
8-K
Novanta boosts share buyback to $231M
Novanta Inc. announced on September 18, 2025, that its board authorized an additional $200 million for repurchasing common shares, boosting total capacity to $231 million including the $31 million left from the 2020 program. Repurchases will occur opportunistically via open market or private deals, guided by market conditions and cash priorities. The flexible program signals confidence in the stock's value. Yet risks from economic shifts could alter execution.
10-Q
Q2 FY2025 results
Novanta's Q2 revenue climbed 2.2% year-over-year to $241.0M, fueled by the April 2025 Keonn acquisition and robust robotics demand, though precision medicine sales dipped. Gross margins edged up to 44.3% on favorable mix, but operating income fell 42.0% to $14.9M amid $12.6M in restructuring and acquisition costs tied to site closures and integration. Diluted EPS dropped to $0.12 from $0.38, reconciling cleanly with 36,076 weighted shares. Cash stood at $109.9M with $536.5M revolver availability under the new $1B facility maturing 2030; free cash flow wasn't disclosed in the 10-Q. Keonn added $6.2M revenue but a $0.7M pre-tax loss, recognizing $44.2M goodwill and $32.3M intangibles amortized over 9-14 years. Economic volatility still pressures customer spending.
8-K
Novanta Q2 revenue up 2%
Novanta Inc. reported Q2 2025 revenue of $241 million, up 2% from last year, driven by acquisitions and favorable currency, yet organic growth dipped 2.1% amid macroeconomic headwinds. GAAP net income fell to $4.5 million from $13.8 million, while adjusted EBITDA edged up to $52 million, reflecting solid execution in high-growth areas like advanced surgery and robotics. Bookings grew 10%, with a 1.02 book-to-bill ratio. The company raised full-year guidance to $970-985 million in revenue and $225-230 million in adjusted EBITDA. Acquisitions boost revenue but elevate integration risks.
8-K
Novanta's general counsel departs
Novanta Inc. announced on July 8, 2025, that General Counsel and Corporate Secretary Michele D. Welsh will depart effective July 18, 2025, or earlier by mutual agreement. Her severance terms under the July 11, 2022, employment agreement remain unchanged. This leadership shift could disrupt legal operations amid ongoing regulatory demands.
IPO
Website
Employees
Sector
Industry
AZTA
Azenta, Inc.
29.79-1.57
ECIA
Encision, Inc.
0.35+0.12
ENOV
Enovis Corporation
31.99-0.87
MBOT
Microbot Medical Inc.
2.13-0.06
MKSI
MKS Inc.
141.40+0.92
NMTC
NeuroOne Medical Technologies C
0.79-0.03
NVMI
Nova Ltd.
351.58+10.63
QSI
Quantum-Si Incorporated
2.14-0.04
SGHT
Sight Sciences, Inc.
5.04-0.13
SSII
SS Innovations International In
8.65+0.13